振德醫療(603301.SH):許昌正德擬投資手術感控生產線擴產建設項目
格隆匯12月31日丨振德醫療(603301.SH)公佈,根據公司戰略發展規劃和業務發展現狀,滿足快速增長的手術感控市場需求,提升手術感控產品產能供應,公司全資子公司許昌正德擬投資手術感控生產線擴產建設項目,項目總投資合計8.45億元。
用於本次投資項目建設用地為河南省許昌市鄢陵縣百花路以東、二級河以南(規劃道路以北)地塊,土地面積為18.52萬平方米。該地塊的國有建設用地使用權已由公司於2020年11月競得。
手術感控產品由各類手術包、手術單、手術衣等組成,該等產品作為外科有創操作中不可缺少的醫用耗材,其目的是建立一個無菌手術創面區,阻止外來物質及微生物侵入手術創面或患者體液、血液,從而避免對術者、醫者及手術環境造成污染。隨着外科手術數量的增長、全面防護觀念轉變及對感染控制措施的加強,手術感控產品市場呈持續增長態勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.